SMS Pharmaceuticals cuts FY27 growth target to 15% on geopolitical risk
The company lowered its revenue guidance from 20% while shifting focus toward higher-margin API segments to protect profitability.
— 3 earlier stories on SMS Pharmaceuticals Ltd. →What's new
- Management cut FY27 revenue growth guidance to 15% from 20% due to Middle East supply chain disruptions.
- The company pivoted resources from anti-diabetic drugs to higher-margin ARV and anti-inflammatory APIs.
- Backward integration into Ibuprofen now accounts for 20% of revenue, shielding margins from cost spikes.
Why this matters
The guidance cut is a direct reaction to external volatility, yet the shift toward specialized API segments suggests a defensive strategy to maintain margins. Investors should watch whether the Rs 280 crore capex program can deliver the promised high-margin product mix by FY28.
What we're watching
- Whether the external environment stabilizes to allow a return to 20-25% growth.
- Execution of the Rs 280 crore capex plan for new API capacity.
- Progress on the goal to reach 60% revenue contribution from high-value APIs.
The full read
SMS Pharmaceuticals reported a 13% revenue rise to Rs 887 crore for FY26 with EBITDA margins of 20%.
Growth is slowing.
Management lowered its FY27 revenue growth guidance to 15% from 20%, citing geopolitical disruptions in the Middle East that are currently snarling supply chains. To counter these pressures, the company is pivoting away from its anti-diabetic segment to focus on ARV and anti-inflammatory APIs, while backward integration into Ibuprofen intermediates now accounts for 20% of revenue to provide a buffer against recent cost volatility. Looking ahead, management targets an EBITDA margin of 22% for FY27, supported by a Rs 280 crore capex program that is set to introduce new high-margin APIs starting in FY28. While the guidance cut reflects immediate external risks, the company is betting that its product-mix shift and vertical integration will sustain profitability through a difficult period.
Questions answered
- Why did SMS Pharmaceuticals lower its revenue guidance?
- Management cited geopolitical disruptions in the Middle East that are currently affecting supply chains. They reduced the target from 20% to 15% for FY27.
- How is the company protecting its margins?
- The company is utilizing backward integration into Ibuprofen intermediates, which now represents 20% of revenue. This integration helped the firm maintain margins during recent cost spikes.
- What is the status of the company's product portfolio?
- Management shifted resources away from the anti-diabetic segment in Q3 FY26 to prioritize ARV and anti-inflammatory APIs. They aim to increase the share of high-value APIs to 60% of total revenue.
- What are the financial targets for FY27?
- The company is targeting 15% revenue growth and an EBITDA margin of 22% for FY27.
Story so far
All notes on SMSPHARMA →- 27 May 2026 · 11:51 AM IST SMS Pharmaceuticals cuts FY27 growth target to 15% on geopolitical risk
- 5d ago SMS Pharmaceuticals books ₹87.61 cr annual profit
- 5d ago SMS Pharmaceuticals hits ₹87.61 cr profit as FY26 growth hits target
- 5d ago SMS Pharmaceuticals grows FY26 revenue to ₹886.87 cr